StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) stock

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)

Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –

Earnings

Amneal Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 26, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$863.00M
+9.9% on a year earlier
Adjusted diluted earnings per share, Q3 FY2026
$0.26
$0.17 a year earlier
Latest guidance
Raised
Nov 3, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of Amneal Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 26, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026before the open$863.00M+9.9%-$0.06$0.26Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026before the open$796.00M+9.8%$0.18$0.30Release
Q1 FY2026ended Mar 31, 2026May 7, 2026during market hours$723.00M+4.0%$0.19$0.27Release
Q4 FY2025ended Dec 31, 2025Feb 27, 2026before the open$814.00M+11.4%$0.11$0.21Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025before the open$785.00M+11.8%$0.01$0.17Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open$725.00M–$0.07$0.25Release
Q1 FY2025ended Mar 31, 2025May 2, 2025before the open$695.00M+5.5%$0.04$0.21Release
Q4 FY2024ended Dec 31, 2024Feb 28, 2025before the open$731.00M+18.5%-$0.10$0.12Release
Q3 FY2024ended Sep 30, 2024Nov 8, 2024before the open$702.00M+13.2%$0.00$0.16Release
Q2 FY2024ended Jun 30, 2024Aug 9, 2024before the open––––Release
Q1 FY2024ended Mar 31, 2024May 3, 2024before the open$659.00M+18.1%-$0.30$0.14Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Amneal Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Net revenueGAAPFY2026$3.15B – $3.25B$3.05B – $3.15BRaisedNov 3, 2026
Adjusted EBITDAnon-GAAPFY2026$800.00M – $815.00M$740.00M – $770.00MRaisedNov 3, 2026
Adjusted diluted EPSnon-GAAPFY2026$1.04 – $1.08$0.95 – $1.05RaisedNov 3, 2026
Capital expendituresFY2026$150.00M$110.00MRaisedNov 3, 2026
Capital expendituresGAAPFY2026$110.00M–NewFeb 27, 2026
Operating cash flowGAAPFY2026$325.00M – $375.00M$350.00M – $400.00MLoweredNov 3, 2026
Operating cash flow, excluding discrete itemsnon-GAAPFY2026$350.00M – $400.00M$375.00M – $425.00MLoweredNov 3, 2026

Guidance vs results

The last range Amneal Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Adjusted diluted EPS$0.75 – $0.80$0.84Σ4QAbove range
FY2025Revenue$3.00B – $3.10B$3.02BΣ4QWithin range

Guidance history

Every forecast Amneal Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 3, 2026Capital expendituresFY2026$150.00MRaised
Nov 3, 2026Adjusted EBITDAFY2026$800.00M – $815.00MRaised
Nov 3, 2026Adjusted diluted EPSFY2026$1.04 – $1.08Raised
Nov 3, 2026Operating cash flowFY2026$325.00M – $375.00MLowered
Nov 3, 2026Operating cash flow, excluding discrete itemsFY2026$350.00M – $400.00MLowered
Nov 3, 2026Net revenueFY2026$3.15B – $3.25BRaised
May 7, 2026Capital expendituresFY2026$110.00MNew
May 7, 2026Adjusted EBITDAFY2026$740.00M – $770.00MRaised
May 7, 2026Adjusted diluted EPSFY2026$0.95 – $1.05Raised
May 7, 2026Operating cash flowFY2026$350.00M – $400.00MRaised
May 7, 2026Operating cash flow, excluding discrete itemsFY2026$375.00M – $425.00MRaised
May 7, 2026Net revenueFY2026$3.05B – $3.15BReaffirmed
Feb 27, 2026Capital expendituresFY2026$110.00MNew
Feb 27, 2026Adjusted EBITDAFY2026$720.00M – $760.00MNew
Feb 27, 2026Adjusted diluted EPSFY2026$0.93 – $1.03New
Feb 27, 2026Operating cash flowFY2026$325.00M – $375.00MNew
Feb 27, 2026Operating cash flow, excluding discrete itemsFY2026$350.00M – $400.00MNew
Feb 27, 2026Net revenueFY2026$3.05B – $3.15BNew
Oct 30, 2025Capital expendituresFY2025$100.00MNew
Oct 30, 2025Adjusted EBITDAFY2025$675.00M – $685.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Amneal Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. News
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Update

See a number that looks wrong?